In the VISION trial, Guardant360 ctDNA profiling identified MET kinase domain mutations in 22.2% of patients with MET-amplified NSCLC at progression, most commonly at D1228, Y1230, and D1231. Here, MET is linked to non-small cell lung carcinoma.